Communiqués Vector Science and Therapeutics Corp.

Actions

PAIN

CA92244M1041

Sociétés holdings

Marché Fermé - Toronto S.E. 21:59:55 06/10/2026			Varia. 5j.	Varia. 1 janv.
1,750 ^CAD	-7,89 %		-6,42 %	+3 400,00 %

24/08	Vector Science lance la production de peptides de qualité pharmaceutique	MT
24/08	Vector Science & Therapeutics augmente sa capacité de production de peptides sur le site de LyoGenesis	CI

Communiqués

25/09	Vector Science and Therapeutics Corp. Issues Options	NE
26/08	Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options	AQ
24/08	Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online	AQ
20/08	Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides	AQ
19/08	/C O R R E C T I O N -- Vector Sciences & Therapeutics/	AQ
17/08	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings	AQ
27/07	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
25/07	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
21/07	Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels	AQ
17/07	Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist	AQ
15/07	Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies	AQ
07/07	Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio	AQ
30/06	Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform	AQ
22/06	Gary Payton II Named Chief Athletic Ambassador of Valor	AQ
15/06	Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform	AQ
12/06	Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform	AQ
08/06	Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor	AQ
02/06	Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy	AQ
13/05	Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing	AQ
11/05	/C O R R E C T I O N -- Vector Sciences & Therapeutics/	AQ
06/05	Vector Science & Therapeutics Expands Board of Directors with Appointment of Dr. Alexander Dobranowski and Scott Kelly	AQ